Financial Results
Q3 2026 – Coming soon!
Fresenius will publish its Q3 2026 results on November 4, 2026. The conference call will take place at 1:30 pm (CET). Please find the dial-in details below.
As a service to investors and sell-side analysts, we provide an Aide Memoire ahead of its quiet period starting October 21, 2026. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. The Aide Memoire may prove helpful in assessing Fresenius’ financial performance ahead of the publication of its Q3 2026 financial results on November 4, 2026.
Q3/26 Webcast
Register hereDocuments
Q3/26 Aide Memoire (PDF)Selected Key Figures Q2/2026
GROUP REVENUE 1
€ 5864 m
+6% 2
Q2/25: €5,571 m
GROUP EBIT 1
€ 719 m
+10% 4
Q2/25: €654 m
CORE NET INCOME 1, 3
€ 470 m
+14% 4
Q2/25: €412 m
CORE EPS 1, 3
€ 0.83
+14% 4
Q2/25: €0.73
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Excluding Fresenius Medical Care and Vitrea
4 Constant currency growth
Revenue by business segment
| € in millions | Q2/26 | Q2/25 | Growth at actual rates | Growth at constant rates1 | Organic growth1 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 2,244 | 2,111 | 6% | 7% | 7% | 0% | 38% |
Fresenius Helios | 3,526 | 3,370 | 5% | 4% | 5% | -1% | 60% |
Total | 5,864 | 5,571 | 5% | 5% | 6% | -1% | 100%2 |
-
1 Growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Remaining 2% Corporate/Other revenue
Before special items